Villeurbanne, France

Michel Aigle

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: V.mane Fils. Active years: 2013.


% Patents Active = 100.0


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michel Aigle: Innovator in Aromatic Molecule Production

Introduction

Michel Aigle is a notable inventor based in Villerbanne, France. He has made significant contributions to the field of bioconversion, particularly in the production of aromatic molecules. His innovative work has led to the development of a unique system that utilizes yeast for the production of valuable compounds.

Latest Patents

Michel Aigle holds a patent for a "System for producing aromatic molecules by bioconversion." This patent involves yeast that comprises at least one gene encoding vanillyl alcohol oxidase, with a sequence that is homologous to the specified sequence SEQ ID No. 1. The methods outlined in his patent focus on producing coniferyl alcohol, ferulic acid, and vanillin. He has 1 patent to his name, showcasing his expertise in this specialized area.

Career Highlights

Throughout his career, Michel Aigle has been associated with V. Mane Fils, a company known for its advancements in flavor and fragrance production. His work at the company has allowed him to explore innovative methods for enhancing the production of aromatic compounds.

Collaborations

Michel has collaborated with notable coworkers, including Joseph Zucca and Fanny Lambert. These partnerships have contributed to the development and refinement of his innovative processes.

Conclusion

Michel Aigle's contributions to the field of aromatic molecule production through bioconversion highlight his role as a significant inventor. His patent and work at V. Mane Fils demonstrate his commitment to innovation in this vital area of research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…